This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Therapy with low-dose interferon alfa improves non–human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS), especially nonaggressive forms, probably through a combination of antiangiogenic, antiviral, and immunomodulating effects.^1-2 We report on a new onset of KS in an HIV-negative man undergoing therapy with interferon alfa-2a for cutaneous T-cell lymphoma (CTCL).

Report of a case

On July 10, 1998, an 82-year-old apparently healthy man presented to the Istituto Dermatologico S. Gallicano in Rome, Italy, with diffuse erythroderma, especially on his shoulders (Figure 1), and intense itching on his entire body surface. The itching was persistent and resistant to oral antihistamine therapy. Immunohistochemical analysis of 2 biopsy specimens obtained from skin lesions revealed stage II CTCL. Serological tests were negative for anti–human T-lymphotropic virus 1/2 antibodies.

Figure appears in full text version. Figure 1. Back of patient, with diffuse erythroderma on shoulders.

Since the regression of CTCL can be achieved with interferon alfa regimens, including interferon alfa combined with photochemotherapy, through intralesional . . . [Full Text of this Article]

Conclusions